Virpax Pharmaceuticals Stock Performance
| VRPX Stock | USD 0.01 0.00 0.00% |
Virpax Pharmaceuticals holds a performance score of 11 on a scale of zero to a hundred. The entity has a beta of 13.63, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Virpax Pharmaceuticals will likely underperform. Use Virpax Pharmaceuticals standard deviation and the relationship between the treynor ratio and day typical price , to analyze future returns on Virpax Pharmaceuticals.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Virpax Pharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Virpax Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Virpax |
Virpax Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2.10 in Virpax Pharmaceuticals on November 17, 2025 and sell it today you would lose (1.00) from holding Virpax Pharmaceuticals or give up 47.62% of portfolio value over 90 days. Virpax Pharmaceuticals is currently generating 19.3057% in daily expected returns and assumes 136.4315% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Virpax, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Virpax Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Virpax Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.01 | 90 days | 0.01 | about 68.39 |
Based on a normal probability distribution, the odds of Virpax Pharmaceuticals to move above the current price in 90 days from now is about 68.39 (This Virpax Pharmaceuticals probability density function shows the probability of Virpax Pink Sheet to fall within a particular range of prices over 90 days) .
Virpax Pharmaceuticals Price Density |
| Price |
Predictive Modules for Virpax Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Virpax Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Virpax Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Virpax Pharmaceuticals is not an exception. The market had few large corrections towards the Virpax Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Virpax Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Virpax Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 30.95 | |
β | Beta against Dow Jones | 13.63 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | 0.13 |
Virpax Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Virpax Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Virpax Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Virpax Pharmaceuticals is way too risky over 90 days horizon | |
| Virpax Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Virpax Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Virpax Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (12.07 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Virpax Pharmaceuticals currently holds about 26.06 M in cash with (16.71 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Virpax Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Virpax Pink Sheet often depends not only on the future outlook of the current and potential Virpax Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Virpax Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.3 M | |
| Cash And Short Term Investments | 1.5 B |
Virpax Pharmaceuticals Fundamentals Growth
Virpax Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Virpax Pharmaceuticals, and Virpax Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Virpax Pink Sheet performance.
| Return On Equity | -23.65 | |||
| Return On Asset | -1.35 | |||
| Current Valuation | (1.21 M) | |||
| Shares Outstanding | 1.24 M | |||
| Price To Book | 0.48 X | |||
| EBITDA | (12.08 B) | |||
| Cash And Equivalents | 26.06 M | |||
| Cash Per Share | 2.22 X | |||
| Total Debt | 2.47 B | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | (1.53) X | |||
| Cash Flow From Operations | (16.71 B) | |||
| Earnings Per Share | (71.00) X | |||
| Total Asset | 1.56 B | |||
| Retained Earnings | (71.61 B) | |||
About Virpax Pharmaceuticals Performance
Evaluating Virpax Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Virpax Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Virpax Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Virpax Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.Things to note about Virpax Pharmaceuticals performance evaluation
Checking the ongoing alerts about Virpax Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Virpax Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Virpax Pharmaceuticals is way too risky over 90 days horizon | |
| Virpax Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Virpax Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Virpax Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (12.07 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Virpax Pharmaceuticals currently holds about 26.06 M in cash with (16.71 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Virpax Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Virpax Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Virpax Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Virpax Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Virpax Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Virpax Pharmaceuticals' pink sheet. These opinions can provide insight into Virpax Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Virpax Pink Sheet Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.